meta|Evidence - COVID-19
click on circles to display study description...
discontinuation of ACEI/ARB (n=77) vs. continuation of ACEI/ARB (n=75)
randomized controlled trial risk of bias NA
discontinue ACEI or ARB therapy
continue ACEI or ARB therapy
COVID 19 hospitalized
open-label
20 large referral hospitals in seven countries worldwide
discontinuation of ACEI/ARB (n=371) vs. continuation of ACEI/ARB (n=369)
randomized controlled trial some concerns about risk of bias
Discontinuation of ACEIs or ARBs
Other drugs could replace these agents at the discretion of the treating physician.β-Blockers were maintained in patients already taking them for heart failure.
Continuation of ACEIs or ARBs
The study protocol did not recommend any specific treatment modification beyond discontinuing or continuing use of ACEIs or ARBs.
COVID-19 mild to moderate
Hospitalized patients with confirmed COVID-19 diagnosis, using ACEI or ARBs; Age ≥18 years; Using no more than 3 antihypertensive drugs; Ability of patient (or legal representative) to provide informed consent.
Open-label.
Multicenter, 29 sites in Brazil.
Outcome calculated for each patient by subtracting the number of days in the hospital and the number of days from death until the end of follow-up from 30 days.
powered by vis.js Network